Valuation: EnteroMedics Inc

Market Cap 1.52Cr 1.32Cr 1.23Cr 1.13Cr 2.14Cr 144.87Cr 2.17Cr 15Cr 5.68Cr 72Cr 5.72Cr 5.59Cr 239.96Cr P/E 2026 *
-3.08x
P/E 2027 * -2.37x
Enterprise Value 1.52Cr 1.32Cr 1.23Cr 1.13Cr 2.14Cr 144.87Cr 2.17Cr 15Cr 5.68Cr 72Cr 5.72Cr 5.59Cr 239.96Cr EV / Sales 2026 *
102x
EV / Sales 2027 * 60.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 2L 1L 1L 1L 2L 1.43Cr 2L 14.32L 6L 71.33L 6L 6L 2.36Cr 2L 2L 2L 2L 4L 2.38Cr 4L 23.86L 9L 1.19Cr 9L 9L 3.94Cr
Net income -48.9L -42.46L -39.59L -36.37L -68.78L -47Cr -69.54L -4.67Cr -1.82Cr -23Cr -1.84Cr -1.8Cr -77Cr -77.69L -67.46L -62.9L -57.78L -1.09Cr -74Cr -1.1Cr -7.42Cr -2.9Cr -37Cr -2.92Cr -2.85Cr -122.4Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-